Passage Bio Gets FDA Clearance of Application for Treatment of Metachromatic Leukodystrophy

 Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PBML04, an adeno-associated virus (AAV)-delivery gene therapy that is being studied for the treatment of Metachromatic Leukodystrophy (MLD). MLD is a rare, fatal, pediatric, lysosomal storage disease that currently has limited available treatment options.

https://www.biospace.com/article/releases/passage-bio-receives-fda-clearance-of-ind-application-for-pbml04-for-treatment-of-metachromatic-leukodystrophy/